Eksponering for losartan i 2. og 3. trimester inducerer føtotoksicitet hos mennesker (nedsat nyrefunktion, oligohydramnios, forsinket kranieossifikation) og neonatal toksicitet (nyresvigt,
Losartan therapy exposure during the second and third trimesters is known to induce human fetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia) (see also 5.3'Preclinical safety data ').